Altimmune Inc reports results for the quarter ended June 30 - Earnings Summary

• Altimmune Inc ALT.OQ reported a quarterly adjusted loss of 27 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -35 cents. The mean expectation of nine analysts for the quarter was for a loss of 32 cents per share. Wall Street expected results to range from -42 cents to -26 cents per share.

• Revenue held steady 0% to $5.00 thousand from a year ago; analysts expected $1.25 thousand.

• Altimmune Inc's reported EPS for the quarter was a loss of 27 cents​.

• The company reported a quarterly loss of $22.18 million.

• Altimmune Inc shares had fallen by 12.7% this quarter and lost 53.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 0.6% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Altimmune Inc is $19.00, about 82.2% above its last closing price of $3.38

This summary was machine generated from LSEG data August 12 at 01:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)